A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Janssen Research & Development, LLC
274 participants
Sep 19, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Eligibility
Inclusion Criteria3
- Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
- Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study
- Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
No study intervention will be administered as part of this LTE study.
No study intervention will be administered as part of this LTE study.
Locations(104)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06635148